Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies
- DOI
- 10.1016/j.urolonc.2026.06.028
- Published
- 2026-09
- Container
- Urologic Oncology: Seminars and Original Investigations
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.urolonc.2026.06.028,
title = {Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies},
author = {Joseph McGrath and Robert Willis and Sudharshanan Balaji and Yudai Ishiyama and Hunter Sceats and Mark Bandyk and KC Balaji},
year = {2026},
journal = {Urologic Oncology: Seminars and Original Investigations},
doi = {10.1016/j.urolonc.2026.06.028},
url = {https://doi.org/10.1016/j.urolonc.2026.06.028}
}RIS
TY - JOUR TI - Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies AU - Joseph McGrath AU - Robert Willis AU - Sudharshanan Balaji AU - Yudai Ishiyama AU - Hunter Sceats AU - Mark Bandyk AU - KC Balaji PY - 2026 JO - Urologic Oncology: Seminars and Original Investigations DO - 10.1016/j.urolonc.2026.06.028 UR - https://doi.org/10.1016/j.urolonc.2026.06.028 ER -
APA
McGrath, J., Willis, R., Balaji, S., Ishiyama, Y., Sceats, H., Bandyk, M., & Balaji, K. (2026). Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2026.06.028
Source records
- crossref · retrieved 2026-09-26T18:19:47.430Z